The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | Interim Phase II results of rapcabtagene autoleucel in first-line high-risk large B-cell lymphoma
In this interview, Pere Barba, MD, PhD, Vall D’Hebron University Hospital, Barcelona, Spain, presents the interim results of a Phase II trial (NCT03960840) evaluating rapcabtagene autoleucel (YTB323) in first-line high-risk large B-cell lymphoma (LBCL), highlighting promising early efficacy and a favorable safety profile. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, I’m very excited because I presented this data, the interim data of this clinical trial, ongoing Phase II clinical trial of YTB323 in patients with high-risk patients with large B-cell lymphoma in first-line treatment. So, these patients had received two prior cycles of therapies, so two cycles of immunochemotherapy and then they underwent an evaluation, a PET scan, and if they were in partial remission or stable disease they could enter into the trial, they received an additional bridging therapy, usually an additional cycle of immunochemotherapy, and then a single dose of YTB323...
So, I’m very excited because I presented this data, the interim data of this clinical trial, ongoing Phase II clinical trial of YTB323 in patients with high-risk patients with large B-cell lymphoma in first-line treatment. So, these patients had received two prior cycles of therapies, so two cycles of immunochemotherapy and then they underwent an evaluation, a PET scan, and if they were in partial remission or stable disease they could enter into the trial, they received an additional bridging therapy, usually an additional cycle of immunochemotherapy, and then a single dose of YTB323. So what we basically observed was a very high probability of complete remission rate over 70%, actually more than 80%, and a complete remission rate of 77%. And the median duration of response and progression-free survival was not reached with a relatively limited follow-up of six months. In terms of safety, this product demonstrated to be very safe with no grade three or higher CRS events and only one grade three ICANS event, and we also observed a robust expansion around two weeks after infusion, and these results open the door to continue investigating this product in first-line R/R format.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory Board and consultancy: Amgen, AstraZeneca, Autolus, BMS/Celgene, Kite/Gilead, Incyte, Novartis, Pfizer and Pierre Fabre.
